Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Files An 8-K Other Events
Item 8.01.Other Events.

On July 24, 2017, Reata Pharmaceuticals, Inc. (the “Company”) issued a press release reporting initial data from the ongoing open-label Phase 2 portion of CARDINAL, a Phase 2/3 trial evaluating bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome (“CARDINAL”).Based upon these data, the Company also reported that it has initiated screening in the Phase 3 portion of the trial. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

The Company plans to hold a conference call on July 24, 2017, at 8:30 a.m. EDT to discuss the initial data from the open-label Phase 2 portion of CARDINAL and the initiation of screening in the Phase 3 portion of the trial. Information about how to access the conference call is in the press release attached as Exhibit 99.1. The presentation slides that are to be used in connection with the conference call are attached as Exhibit 99.2 and incorporated herein by reference.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K and oral statements made with respect to information contained in this report may contain forward looking information within the meaning of the Private Securities Litigation Reform Act of 1995. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms. These forward-looking statements include, but are not limited to, statements about the CARDINAL trial.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our expectations regarding the timing, costs, conduct, and outcome of our clinical trials, including statements regarding the timing of the initiation and availability of data from such trials; the timing and likelihood of regulatory filings and approvals for our product candidates; our expectations regarding the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the potential market opportunities for commercializing our product candidates; our expectations related to the use of our available cash; estimates of our expenses, future revenue, capital requirements, and our needs for additional financing; our ability to develop, acquire, and advance product candidates into, and successfully complete, clinical trials; the initiation, timing, progress, and results of future preclinical studies and clinical trials, and our research and development programs; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates; our ability to maintain and establish collaborations or obtain additional funding; our ability to maintain and establish relationships with third parties, such as contract research organizations, suppliers, and distributors; our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; our ability to establish and maintain arrangements for manufacture of our product candidates; the impact of governmental laws and regulations; developments and projections relating to our competitors and our industry; and other risks and uncertainties included in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available on the Investor & News section of www.reatapharma.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

Item 8.01.Financial Statements and Exhibits.

(d)Exhibits

REATA PHARMACEUTICALS INC Exhibit
EX-99.1 2 reta-ex991_194.htm EX-99.1 PRESS RELEASE CARDINAL reta-ex991_194.htm Exhibit 99.1         Reata’s bardoxolone methyl DEMONSTRATED improved kidney function in patients with alport syndrome in ONGOING phase 2 portion of Phase 2/3 cardinal Study   Screening of patients in Phase 3 portion of Cardinal underway   Planning to initiate additional rare chronic kidney disease programs   Conference Call with management scheduled today at 8:30am ET IRVING,…
To view the full exhibit click here

About Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma.